{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T18:13:03Z","timestamp":1795111983930,"version":"4.10.3"},"reference-count":45,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"7","license":[{"start":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T00:00:00Z","timestamp":1703721600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>CD47-SIRPa is a myeloid check point pathway that promotes phagocytosis of cells lacking markers for self-recognition. Tumor cells can overexpress CD47 and bind to SIRPa on macrophages, preventing phagocytosis. CD47 expression is enhanced and correlated with a negative prognosis in acute myeloid leukemia (AML), with its blockade leading to cell clearance. ALX90 is an engineered fusion protein with high affinity for CD47. Composed of the N-terminal D1 domain of SIRP\u03b1 genetically linked to an inactive Fc domain from human immunoglobulin (Ig) G, ALX90 is designed to avoid potential toxicity of CD47-expressing red blood cells. Venetoclax (VEN) is a specific B-cell lymphoma-2 (BCL-2) inhibitor that can restore apoptosis in malignant cells. In AML, VEN is combined with azanucleosides to induce superior remission rates, however treatment for refractory\/relapse is an unmet need. We questioned whether the anti-tumor activity of a VENbased regimen can be augmented through CD47 inhibition (CD47i) in AML and how this triplet may be enhanced. Human AML cell lines were sensitive to ALX90 and its addition increased efficacy of a VEN plus azacitidin (VEN+AZA) regimen in vivo. However, CD47i failed to clear bone marrow tumor burden in PDX models. We hypothesized that the loss of resident macrophages in the bone marrow in AML reduced efficiency of CD47i. Therefore, we attempted to enhance this medullary macrophage population with agonism of TLR3 via polyinosinic:polycytidylic acid (poly(I:C)), which led to expansion and activation of medullary macrophages in in vivo AML PDX models and potentiated CD47i. In summary, the addition of poly(I:C) can enhance medullary macrophage populations to potentiate the phagocytosis merited by therapeutic inhibition of CD47.<\/jats:p>","DOI":"10.3324\/haematol.2023.283850","type":"journal-article","created":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T02:51:57Z","timestamp":1703731917000},"page":"2111-2121","source":"Crossref","is-referenced-by-count":10,"title":["TLR3 agonism augments CD47 inhibition in acute myeloid leukemia"],"prefix":"10.3324","volume":"109","author":[{"given":"Haley E.","family":"Ramsey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka E.","family":"Gorska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna N.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Monteith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Londa","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria P.","family":"Arrate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Savona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,12,28]]},"reference":[{"key":"63081","doi-asserted-by":"crossref","unstructured":"Kelley SM, Ravichandran KS. Putting the brakes on phagocytosis: \u201cdon\u2019t-eat-me\u201d signaling in physiology and disease. EMBO Rep. 2021; 22(6):e52564.","DOI":"10.15252\/embr.202152564"},{"key":"63082","doi-asserted-by":"crossref","unstructured":"Jaiswal S, Jamieson CHM, Pang WW. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009; 138(2):271-285.","DOI":"10.1016\/j.cell.2009.05.046"},{"key":"63083","doi-asserted-by":"crossref","unstructured":"Sikic BI, Lakhani N, Patnaik A. First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. J Clin Oncol. 2019; 37(12):946-953.","DOI":"10.1200\/JCO.18.02018"},{"key":"63084","doi-asserted-by":"crossref","unstructured":"Advani R, Flinn I, Popplewell L. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma. N Engl J Med. 2018; 379(18):1711-1721.","DOI":"10.1056\/NEJMoa1807315"},{"key":"63085","doi-asserted-by":"crossref","unstructured":"Wang Y, Ni H, Zhou S. Tumor-selective blockade of CD47 signaling with a CD47\/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity. Cancer Immunol Immunother. 2021; 70(2):365-376.","DOI":"10.1007\/s00262-020-02679-5"},{"key":"63086","doi-asserted-by":"crossref","unstructured":"Chen SH, Dominik PK, Stanfield J. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity. J Immunother Cancer. 2021; 9(10):e003464.","DOI":"10.1136\/jitc-2021-003464"},{"key":"63087","doi-asserted-by":"crossref","unstructured":"Dheilly E, Moine V, Broyer L. Selective blockade of the ubiquitous checkpoint receptor CD47 is enabled by dual-targeting bispecific antibodies. Mol Ther. 2017; 25(2):523-533.","DOI":"10.1016\/j.ymthe.2016.11.006"},{"key":"63088","doi-asserted-by":"crossref","unstructured":"Lakhani NJ, Chow LQM, Gainor JF. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and doseexpansion study. Lancet Oncol. 2021; 22(12):1740-1751.","DOI":"10.1016\/S1470-2045(21)00584-2"},{"key":"63089","doi-asserted-by":"crossref","unstructured":"Kauder SE, Kuo TC, Harrabi O. ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile. PLoS One. 2018; 13(8):e0201832.","DOI":"10.1371\/journal.pone.0201832"},{"key":"63090","doi-asserted-by":"crossref","unstructured":"Kuo TC, Chen A, Harrabi O. Targeting the myeloid checkpoint receptor SIRPalpha potentiates innate and adaptive immune responses to promote anti-tumor activity. J Hematol Oncol. 2020; 13(1):160.","DOI":"10.1186\/s13045-020-00989-w"},{"key":"63091","doi-asserted-by":"crossref","unstructured":"Konopleva M, Pollye DA, Potluri J. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016; 6(10):1106-1117.","DOI":"10.1158\/2159-8290.CD-16-0313"},{"key":"63092","doi-asserted-by":"crossref","unstructured":"Nechiporuk T, Kurtz SE, Nikolova O. The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells. Cancer Discov. 2019; 9(7):910-925.","DOI":"10.1158\/2159-8290.CD-19-0125"},{"key":"63093","doi-asserted-by":"crossref","unstructured":"Wei AH, Strickland Jr SA, Hou J-Z. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II Study. J Clin Oncol. 2019; 37(15):1277-1284.","DOI":"10.1200\/JCO.18.01600"},{"key":"63094","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Pratz K, Pullarkat V. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019; 133(1):7-17.","DOI":"10.1182\/blood-2018-08-868752"},{"key":"63095","doi-asserted-by":"crossref","unstructured":"Ivanov V, Yeh S-P, Mayer J. Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia. Future Oncol. 2022; 18(26):2879-2889.","DOI":"10.2217\/fon-2022-0450"},{"key":"63096","doi-asserted-by":"crossref","unstructured":"Kim K, Maiti A, Loghavi S. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. Cancer. 2021; 127(20):3772-3781.","DOI":"10.1002\/cncr.33689"},{"key":"63097","doi-asserted-by":"crossref","unstructured":"Ramsey HE, Fischer MA, Lee T. A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia. Cancer Discov. 2018; 8(12):1566-1581.","DOI":"10.1158\/2159-8290.CD-18-0140"},{"key":"63098","doi-asserted-by":"crossref","unstructured":"Deleidi M, Hallett PJ, Koprich JB, Chung CY, Isacson O. The Toll-like receptor-3 agonist polyinosinic:polycytidylic acid triggers nigrostriatal dopaminergic degeneration. J Neurosci. 2010; 30(48):16091-16101.","DOI":"10.1523\/JNEUROSCI.2400-10.2010"},{"key":"63099","doi-asserted-by":"crossref","unstructured":"Wang A, Kang X, Wang J, Zhang S. IFIH1\/IRF1\/STAT1 promotes sepsis associated inflammatory lung injury via activating macrophage M1 polarization. Int Immunopharmacol. 2023; 114:109478.","DOI":"10.1016\/j.intimp.2022.109478"},{"key":"63100","doi-asserted-by":"crossref","unstructured":"Anfray C, Mainini F, Digifico E. Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity. J Immunother Cancer. 2021; 9(9):e002408.","DOI":"10.1136\/jitc-2021-002408"},{"key":"63101","doi-asserted-by":"crossref","unstructured":"Xu ZJ, Gu Y, Wang CZ. The M2 macrophage marker CD206: a novel prognostic indicator for acute myeloid leukemia. Oncoimmunology. 2020; 9(1):1683347.","DOI":"10.1080\/2162402X.2019.1683347"},{"key":"63102","doi-asserted-by":"crossref","unstructured":"Anderson NR, Minutolo NG, Gill S, Klichinsky M. Macrophage-based approaches for cancer immunotherapy. Cancer Res. 2021; 81(5):1201-1208.","DOI":"10.1158\/0008-5472.CAN-20-2990"},{"key":"63103","doi-asserted-by":"crossref","unstructured":"Madeddu C, Gramignano G, Kotsonis P. Microenvironmental M1 tumor-associated macrophage polarization influences cancer-related anemia in advanced ovarian cancer: key role of interleukin-6. Haematologica. 2018; 103(9):e388-e391.","DOI":"10.3324\/haematol.2018.191551"},{"key":"63104","doi-asserted-by":"crossref","unstructured":"Vidyarthi A, Khan N, Agnihotri T. TLR-3 stimulation skews M2 macrophages to M1 through IFN-alphabeta signaling and restricts tumor progression. Front Immunol. 2018; 9:1650.","DOI":"10.3389\/fimmu.2018.01650"},{"key":"63105","doi-asserted-by":"crossref","unstructured":"Xie C, Liu C, Wu B. Effects of IRF1 and IFN-beta interaction on the M1 polarization of macrophages and its antitumor function. Int J Mol Med. 2016; 38(1):148-160.","DOI":"10.3892\/ijmm.2016.2583"},{"key":"63106","doi-asserted-by":"crossref","unstructured":"DeKelver RC. RUNX1-ETO induces a type I interferon response which negatively effects t(8;21)-induced increased self-renewal and leukemia development. Leuk Lymphoma. 2014; 55(4):884-891.","DOI":"10.3109\/10428194.2013.815351"},{"key":"63107","doi-asserted-by":"crossref","unstructured":"Ishikawa H, Ma Z, Barber GN. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature. 2009; 461(7265):788-792.","DOI":"10.1038\/nature08476"},{"key":"63108","doi-asserted-by":"crossref","unstructured":"Alsufyani A, Alanazi R, Woolley JF, Dahal LN. Old Dog, New trick: type I IFN-based treatment for acute myeloid leukemia. Mol Cancer Res. 2021; 19(5):753-756.","DOI":"10.1158\/1541-7786.MCR-20-0871"},{"key":"63109","doi-asserted-by":"crossref","unstructured":"Muller E, Christopoulos PF, Halder S. Toll-like receptor ligands and interferon-gamma synergize for induction of antitumor M1 macrophages. Front Immunol. 2017; 8:1383.","DOI":"10.3389\/fimmu.2017.01383"},{"key":"63110","doi-asserted-by":"crossref","unstructured":"Munoz-Rojas AR, Kelsey I, Pappalardo JL, Chen M, Miller-Jensen K. Co-stimulation with opposing macrophage polarization cues leads to orthogonal secretion programs in individual cells. Nat Commun. 2021; 12(1):301.","DOI":"10.1038\/s41467-020-20540-2"},{"key":"63111","doi-asserted-by":"crossref","unstructured":"Lu S, Li D, Xi L, Calderone R. Interplay of interferon-gamma and macrophage polarization during Talaromyces marneffei infection. Microb Pathog. 2019; 134:103594.","DOI":"10.1016\/j.micpath.2019.103594"},{"key":"63112","doi-asserted-by":"crossref","unstructured":"Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001; 413(6857):732-738.","DOI":"10.1038\/35099560"},{"key":"63113","doi-asserted-by":"crossref","unstructured":"Zhong C, Wang L, Hu S. Poly(I:C) enhances the efficacy of phagocytosis checkpoint blockade immunotherapy by inducing IL-6 production. J Leukoc Biol. 2021; 110(6):1197-1208.","DOI":"10.1002\/JLB.5MA0421-013R"},{"key":"63114","unstructured":"Ewel CH, Urba WJ, Kopp WC. Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects. Cancer Res. 1992; 52(11):3005-3010."},{"key":"63115","doi-asserted-by":"crossref","unstructured":"Feldman S, Hughes WT, Darlington RW, Kim HK. Evaluation of topical polyinosinic acid-polycytidylic acid in treatment of localized herpes zoster in children with cancer: a randomized, double-blind controlled study. Antimicrob Agents Chemother. 1975; 8(3):289-294.","DOI":"10.1128\/AAC.8.3.289"},{"key":"63116","doi-asserted-by":"crossref","unstructured":"Okada H, Kalinski P, Ueda R. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol. 2011; 29(3):330-336.","DOI":"10.1200\/JCO.2010.30.7744"},{"key":"63117","doi-asserted-by":"crossref","unstructured":"Pollack IF, Jakacki R, Butterfield LH. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. J Clin Oncol. 2014; 32(19):2050-2058.","DOI":"10.1200\/JCO.2013.54.0526"},{"key":"63118","doi-asserted-by":"crossref","unstructured":"Petty AJ, Yang Y. Tumor-associated macrophages: implications in cancer immunotherapy. Immunotherapy. 2017; 9(3):289-302.","DOI":"10.2217\/imt-2016-0135"},{"key":"63119","doi-asserted-by":"crossref","unstructured":"Li X, Liu R, Su X. Harnessing tumor-associated macrophages as aids for cancer immunotherapy. Mol Cancer. 2019; 18(1):177.","DOI":"10.1186\/s12943-019-1102-3"},{"key":"63120","doi-asserted-by":"crossref","unstructured":"Yang X, Feng W, Wang R. Repolarizing heterogeneous leukemia-associated macrophages with more M1 characteristics eliminates their pro-leukemic effects. Oncoimmunology. 2018; 7(4):e1412910.","DOI":"10.1080\/2162402X.2017.1412910"},{"key":"63121","doi-asserted-by":"crossref","unstructured":"Yan X, Lai B, Zhou X. The differential expression of CD47 may be related to the pathogenesis from myelodysplastic syndromes to acute myeloid leukemia. Front Oncol. 2022; 12:872999.","DOI":"10.3389\/fonc.2022.872999"},{"key":"63122","doi-asserted-by":"crossref","unstructured":"Anfray C, Ummarino A, Andon FT, Allavena P. Current strategies to target tumor-associated-macrophages to improve anti-tumor immune responses. Cells. 2019; 9(1):46.","DOI":"10.3390\/cells9010046"},{"key":"63123","doi-asserted-by":"crossref","unstructured":"Gordon SR, Maute RL, Dulken BW. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017; 545(7655):495-499.","DOI":"10.1038\/nature22396"},{"key":"63124","doi-asserted-by":"crossref","unstructured":"Petty AJ, Li A, Wang X. Hedgehog signaling promotes tumor-associated macrophage polarization to suppress intratumoral CD8+ T cell recruitment. J Clin Invest. 2019; 129(12):5151-5162.","DOI":"10.1172\/JCI128644"},{"key":"63125","doi-asserted-by":"crossref","unstructured":"Tang Z, Davidson D, Li R. Inflammatory macrophages exploit unconventional pro-phagocytic integrins for phagocytosis and anti-tumor immunity. Cell Rep. 2021; 37(11):110111.","DOI":"10.1016\/j.celrep.2021.110111"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283850\/76485","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283850\/77166","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11390\/76485","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:27Z","timestamp":1794045927000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,28]]},"references-count":45,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283850","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,28]]}}}